Table 4.
Site-specific cancers by insulin glargine group in the fixed cohort
| Site | Data presented as | Non-glargine insulin | Non-glargine plus glargine insulin | Insulin glargine only | ||
|---|---|---|---|---|---|---|
| Breast cancer | n (%) | 81 (0.5) | 5 (0.3) | 6 (2.6) | ||
| Model 1a (n = 17,151) | HR (95% CI) | Reference | 0.87 (0.34–2.17) | p = 0.76 | 3.39 (1.46–7.85) | p = 0.004 |
| Model 2b (n = 17,151) | HR (95% CI) | Reference | 0.85 (0.34–2.14) | p = 0.73 | 3.92 (1.58–9.70) | p = 0.003 |
| Model 3c (n = 13,635) | HR (95% CI) | Reference | 1.07 (0.42–2.73) | p = 0.88 | 5.04 (1.95–13.03) | p = 0.001 |
| Model 4c (n = 10,307) | HR (95% CI) | Reference | 1.10 (0.38–3.16) | p = 0.86 | 3.65 (1.05–12.68) | p = 0.042 |
| Prostate | n (%) | 44 (0.26) | 3 (0.17) | 1 (0.47) | ||
| Model 1a (n = 19,103) | HR (95% CI) | Reference | 1.76 (0.54–5.74) | p = 0.35 | 1.16 (0.16–8.50) | p = 0.88 |
| Colorectal | 104 (0.32) | 2 (0.06) | 3 (0.67) | |||
| Model 1a (n = 36,254) | HR (95% CI) | Reference | 0.36 (0.09–1.45) | p = 0.15 | 1.43 (0.45–4.57) | p = 0.54 |
| Lung | n (%) | 140 (0.43) | 5 (0.14) | 4 (0.89) | ||
| Model 1a (n = 36,254) | HR (95% CI) | Reference | 0.47 (0.18–1.25) | p = 0.13 | 1.43 (0.53–3.88) | p = 0.49 |
| Pancreatic n (%) | 38 (0.12) | 1 (0.03) | 0 | |||
| Model 1a (n = 36254) | HR (95% CI) | Reference | 0.54 (0.08–4.32) | p = 0.60 | No events | |
aModel 1 adjusts for prior cancer, type of diabetes and calendar year, and is stratified by sex ; timescale is age
bModel 2 further adjusts for metformin, sulfonylurea and other oral hypoglycaemic drugs at baseline
cModel 3 further adjusts for diabetes duration, HbA1c, diastolic BP, systolic BP and deprivation quintile
dModel 4 further adjusts for smoking ever and BMI, but note the reduction in available sample size due to missing covariates